Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C.W. Gerth, C. Hoyer, J. Klosterkötter, M. Hellmich and D. Koethe Translationnal Psychiatry, 2012, 2, e94 doi :10.1038/tp.2012.15; published online 20 March 2012 Abstract Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In [...]
Lire la suiteMultiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Alline Cristina Campos, Fabricio Araujo Moreira, Felipe Villela Gomes, Elaine Aparecida Del Bel and Francisco Silveira Guimaraes Philosophical Transactions of The Royal Society Bulletin, 2012, 367, 3364–3378 doi:10.1098/rstb.2011.0389 Abstract Cannabidiol (CBD) is amajor phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound D9 tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear thatCBDhas therapeutic potential over a [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip Mc Guire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright, American Journal of Psychiatry, 2018, 175, 3, 225-231 https://doi.org/10.1176/appi.ajp.2017.17030325 Abstract Objective: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using [...]
Lire la suiteCOMMENTARY A Physician's Guide to the Cannabidiol Craze Angela Coombs, Diana M. Martinez, Medscape, May 31, 2019 https://www.medscape.com/viewarticle/913273?nlid=130052_425&src=WNL_mdplsfeat_190604_mscpedit_psyc&uac=292598PZ&spon=12&impID=1984514&faf=1 Last month at the Columbia University Department of Psychiatry in upper Manhattan, Columbia chief psychiatry resident Dr Angela Coombs interviewed addiction expert Dr Diana Martinez on a number of issues related to the rising popularity and usage of cannabidiol (CBD). Angela Coombs, MD: Hi. My name is Dr Angela Coombs and I'm a chief resident here at Columbia. We are so happy to be able to have Dr Diana Martinez, who's a professor in psychiatry at Columbia and an expert in addiction psychiatry. Today we are talking about [...]
Lire la suiteCB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain Elisa Nent, Chihiro Nozaki, Anne-Caroline Schmöle, David Otte & Andreas Zimmer www.nature.com/scientificreports, 2019, 9, 7468 https://doi.org/10.1038/s41598-019-43858-4 Abstract : Neuropathic pain can develop after nerve injury, leading to a chronic condition with spontaneous pain and hyperalgesia. Pain is typically restricted to the side of the injured nerve, but may occasionally spread to the contralateral side, a condition that is often referred to as mirror-image pain. Mechanisms leading to mirror-image pain are not completely understood, but cannabinoid CB2 receptors have been implicated. In this study, we use genetic mouse models to [...]
Lire la suiteDoes cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA Francesca N Delling, Eric Vittinghoff, Thomas A Dewland, Mark J Pletcher, Jeffrey E Olgin, Gregory Nah, Kirstin Aschbacher, Christina D Fang, Emily S Lee, Shannon M Fan, Dhruv S Kazi, Gregory M Marcus BMJ Open, 2019, 9:e027432 http:// dx.doi. org/ 10. 1136/ bmjopen- 2018-027432). Abstract Objective : To assess the effect of cannabis legalisation on health effects and healthcare utilisation in Colorado (CO), the first state to legalise recreational cannabis, when compared with two control states, New York (NY) and Oklahoma (OK). Design : We used the [...]
Lire la suiteMedical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida Maija Reblin, Solmaz Sahebjam, Noah C. Peeri, Yessica C. Martinez, Zachary Thompson, and Kathleen M. Egan. Journal of Palliative Medicine, 2019, May 13 https://doi.org/10.1089/jpm.2018.0528 Abstract : Background: Glioma is a devastating primary tumor of the central nervous system with difficult-to-manage symptoms. Cannabis products have been postulated to potentially benefit glioma patients. Recent state legalization allowed investigators an opportunity to study glioma patients' adoption of medical marijuana (MM). Objective: Our goals were to: (1) determine the prevalence of marijuana use, both through physician recommendation and self-medication, and (2) evaluate its perceived risks and [...]
Lire la suiteCannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer Jung Lim Kim, Bo Ram Kim, Dae Yeong Kim, Yoon A. Jeong, Soyeon Jeong, Yoo Jin Na, Seong Hye Park, Hye Kyeong Yun, Min Jee Jo, Bu Gyeom Kim, Han Do Kim, Dae Hyun Kim, Sang Cheul Oh, Sun Il Lee and Dae-Hee Lee Cancers, 2019, 11, 642 DOI : 10.3390/cancers11050642 www.mdpi.com/journal/cancers Abstract : Cannabidiol, a major non-psychotomimetic compound derived from Cannabis sativa, is a potential therapeutic agent for a variety of diseases such as inflammatory diseases, chronic neurodegenerative diseases, and cancers. Here, we found that the combination of cannabidiol and TNF-related [...]
Lire la suiteAdvisory body on drug misuse to provide framework on medical cannabis by end of 2019 The Pharmaceutical Journal, 9 MAY 2019, By Julia Robinson The Pharmaceutical Journal, May 2019, Vol 302, No 7925, online | DOI: 10.1211/PJ.2019.20206487 https://www.pharmaceutical-journal.com/news-and-analysis/news/advisory-body-on-drug-misuse-to-provide-framework-on-medical-cannabis-by-end-of-2019/20206487.article?firstPass=false Source: Charlie Milligan Roger Knaggs says he isn’t surprised about the lack of medical cannabis prescriptions since its reclassification, warning that it will continue until prescribers have a clearer idea about what they should be prescribing The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the aim of having an initial view [...]
Lire la suiteCannabis Where are we and where are we going ? Bilan sur les statuts du cannabis dans le monde Le groupe Edison a publié une revue sur le statut du cannabis dans le monde. Où sommes-nous et où allons-nous? EDISON Healthcare, 30 April 2019 The cannabis sector is relatively broad, spanning FDA-approved drugs toconsumer products. Both markets are still at a fraction of their potential peak sizes due to laws forbidding the use of cannabis and also regulatory hesitance to approve drugs with related active ingredients. Worldwide sales for all regulator-approved cannabinoid therapeutics were only $53m in 2018 while the total legal cannabis market [...]
Lire la suite